Latest Content

Lauren Yerkes shares how her breast cancer diagnosis uncovered generations of genetic information for her family.

Olympians’ resilience and joy offer lessons in strength and support for patients with cancer.

The FDA placed a partial hold on a phase 2 lorigerlimab trial in gynecologic cancers after a patient died from grade 4 neutropenia and septic shock.

Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

In a trial of 171 women, app-based self-acupressure improved fatigue vs usual care, offering a low-cost option for ovarian cancer survivors.

FDA removal of an exclusion allows Yescarta use in primary CNS lymphoma, showing safety and strong efficacy in relapsed disease.

My daughter is happy to tell her story so that others can learn that there is hope in the face of despair.

The U.S. FDA has granted traditional approval to Braftovi with Erbitux and chemo for adults with BRAF V600E metastatic colorectal cancer.

Five-year follow-up of cryoablation for small kidney tumors shows high recurrence-free rates and a minimally invasive option for select patients.

The FDA granted fast track status to ART6043 plus Lynparza for patients with gBRCA-mutated HER2-negative breast cancer to accelerate drug development.

In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma.

Cancer-related fatigue may persist despite improved sleep or treated depression, underscoring it as a distinct and complex symptom.

Dr. William Audeh discusses how genomic subtyping can close the 38% mortality gap for Black women by identifying aggressive basal-type cancers.